Safety and outcomes of open-label deferasirox iron chelation therapy for mucormycosis

Brad Spellberg, David Andes, Mario Perez, Anne Anglim, Hector Bonilla, Glenn E. Mathisen, Thomas J. Walsh, Ashraf S. Ibrahim

Research output: Contribution to journalArticlepeer-review

Abstract

We sought to describe the safety profile of open-label, adjunctive deferasirox iron chelation therapy in eight patients with biopsy-proven mucormycosis. Deferasirox was administered for an average of 14 days (range, 7 to 21) at 5 to 20 mg/kg of body weight/day. The only adverse effects attributable to deferasirox were rashes in two patients. Deferasirox treatment was not associated with changes in renal or liver function, complete blood count, or transplant immunosuppressive levels. Thus, deferasirox appears safe as an adjunctive therapy for mucormycosis.

Original languageEnglish (US)
Pages (from-to)3122-3125
Number of pages4
JournalAntimicrobial agents and chemotherapy
Volume53
Issue number7
DOIs
StatePublished - Jul 2009

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)
  • Infectious Diseases

Fingerprint

Dive into the research topics of 'Safety and outcomes of open-label deferasirox iron chelation therapy for mucormycosis'. Together they form a unique fingerprint.

Cite this